News Sentiment

CRDL sentiment intelligence

Cardiol Therapeutics Inc Class A news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 1.01 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.8% over one week, -1.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend inactive -1.9% over four weeks
Fair value -24.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 26
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingView 8
Market source 6
CNW Group 4
PR Newswire 2
MarketBeat 2
Investing.com Nigeria 1
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 13
Analyst action 4
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 42
Investing.com Nigeria Direct company coverage

H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com

H.C. Wainwright has reiterated a Buy rating for Cardiol Therapeutics (NASDAQ:CRDL) with a $9.00 price target. This re-affirmation follows the publication of the MAvERIC-Pilot study in the Journal of the American Heart Association, which showed positive results for CardiolRx in tr

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 12:39
Source
Investing.com Nigeria
TradingView Direct company coverage

ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks

This article lists ETFs that hold Cardiol Therapeutics Inc. Class A stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each fund. It highlights how these ETFs make stock investing more accessible and offer opportunities with lo

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 16:13
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL

This article displays the "Price to earnings forward" metric for Cardiol Therapeutics Inc. Class A (TSX:CRDL). It indicates the value and change over a period, noting that the data is "Made by humans" and sourced from ICE Data Services and FactSet. The page is from TradingView an

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A – TSX:CRDL

The article focuses on the enterprise value to revenue forward for Cardiol Therapeutics Inc. Class A (TSX: CRDL). It seems to be a financial data point provided by TradingView, indicating a key metric for the company's valuation. However, the provided content mainly consists of n

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL)

This article provides an overview of Cardiol Therapeutics Inc. Class A (TSX:CRDL) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings per share and revenue, and answers frequently ask

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:11
Source
TradingView
TradingView Direct company coverage

Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL)

This article provides an overview of Cardiol Therapeutics Inc. Class A (CRDL) stock performance, including current trading price, historical highs and lows, market capitalization, and analyst forecasts. It also covers the company's financial results, such as recent earnings per s

Tone
Negative 34/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

CRDL Forecast — Price Target — Prediction for 2027

This article provides a forecast for Cardiol Therapeutics Inc. Class A (CRDL) stock, including analyst price targets, historical performance, and key financial data. It highlights that analysts have a maximum price target of 12.30 CAD and a minimum of 6.83 CAD for CRDL. The compa

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 22:09
Source
TradingView
TradingView Direct company coverage

A2PA9E Forecast — Price Target — Prediction for 2027

Cardiol Therapeutics Inc. (A2PA9E) shows a current stock price of 0.9160 EUR, having decreased by 2.97% in 24 hours. Analysts provide a price target forecast with a maximum estimate of 7.69 EUR and a minimum of 4.27 EUR. The company's next earnings report is expected on August 17

Tone
Negative 35/100
Event
Earnings
Published
25 Jun 2026 12:10
Source
TradingView
Stock Titan Direct company coverage

Cardiol shareholders back all AGM resolutions, elect 8 directors

Cardiol Therapeutics Inc. announced that its shareholders approved all management resolutions at the 2026 Annual General Meeting held virtually on June 24, 2026. This included the election of eight directors with overwhelming support (between 96.24% and 99.19% of votes cast) and

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 07:27
Source
Stock Titan
Market source Direct company coverage

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ on May 19, 2026. The company, a late-stage life sciences firm, is focused on developing anti-inflammatory and anti-fibrotic therapies for h

Tone
Positive 67/100
Event
Market update
Published
21 May 2026 06:09
Source
Market source
Stock Titan Direct company coverage

[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure

MMCAP International Inc. SPC and MM Asset Management Inc. have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Cardiol Therapeutics Inc., reporting shared beneficial ownership of 21,063,856 Class A Common Shares, which represents 17.9% of the class as of March

Tone
Neutral 50/100
Event
Market update
Published
15 May 2026 20:39
Source
Stock Titan
FinancialContent Direct company coverage

Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL)

This article provides news headlines related to Cardiol Therapeutics Inc. (Nasdaq: CRDL). Key updates include the FDA approving Cardiol's Investigational New Drug application for CardiolRx to test an oral cannabidiol formulation in acute myocarditis patients, and the company's st

Tone
Positive 72/100
Event
Regulatory and legal
Published
15 May 2026 04:39
Source
FinancialContent
Market source Direct company coverage

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics will participate in a live interview with Barchart on April 14, 2026, to discuss its MAVERIC Phase III trial for recurrent pericarditis and results from the ARCHER Phase II trial for acute myocarditis. The interview will feature Cardiol's President and CEO, D

Tone
Positive 70/100
Event
Earnings
Published
16 Apr 2026 02:39
Source
Market source
The Globe and Mail Direct company coverage

Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders

Cardiol Therapeutics has announced that its Annual General Meeting of Shareholders will be held on June 24, 2026, with May 7, 2026, set as the record date for voting eligibility. The company, a foreign private issuer reporting under Form 40-F, also detailed its use of notice-and-

Tone
Neutral 50/100
Event
Market update
Published
12 Apr 2026 01:39
Source
The Globe and Mail